Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, NuProbe Partner on Rare Variant Enrichment in Liquid Biopsy Tests

NEW YORK – NuProbe and Qiagen have entered into a strategic collaboration to develop next-generation sequencing-based cancer liquid biopsy tests, the firms announced Monday.

Under the terms of their agreement, NuProbe and Qiagen will explore integration of their amplicon-based target enrichment technologies — NuProbe's blocker displacement amplification (BDA) and Qiagen's single primer extension technology — to analyze DNA mutations with low variant allele fractions.

The partners will initially develop a research-use only product for clinical oncology, but said in a statement they "may explore further strategic collaboration and develop other commercial products."

Financial and other terms of the agreement were not disclosed.

"We are excited about the potential products that will come out of the two synergistic rare variant enrichment and detection methods," Yingshuang Chai, NuProbe CEO and chairman, said in a statement. "This collaboration further demonstrates the adoption of our cutting-edge technology by industry leaders."

The deal is the third partnership this year for NuProbe, a Wyss Institute spinout that completed a merger with China's CarrierGene Biotech earlier this year. In January, the company announced a partnership with Illumina to offer target enrichment assays and in February Oxford Nanopore Technologies licensed NuProbe's BDA tech to help expand into cancer research. 

Qiagen's business relationships have recently been in flux. In October 2019, the firm announced that it would discontinue development of its GeneReader sequencing platform and would partner with Illumina to develop diagnostic panels. Earlier this month, Thermo Fisher Scientific said it would buy Qiagen for $11.5 billion in cash.

Last week, Natera terminated its license, development, and distribution agreement with Qiagen, citing the Illumina deal.

NuProbe also announced it has submitted five CE-IVD registrations for products including liquid biopsy tests for EGFR and BRAF gene mutations. NuProbe plans on obtaining CE-IVD and China National Medical Products Administration registration for additional products, the firm said.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.